Biotech Values

[DewDiligence]

ABT – Investors expect too much from Humira, IMO. How many other $5B drugs are growing at 33% per year? Not many.

All told, I thought ABT turned in a decent quarter given the YoY hit from the strong dollar and the loss of exclusivity on Depakote.

Xience is a monster product that could conceivably top Humira in worldwide sales in due course. Moreover, Certriad, the Crestor + TriLipix combo pill, has the makings of a very big-selling drug (#msg-38514635).

If Certriad attains its potential, ABT could have three simultaneous mega-blockbusters, which is something that very few pharma companies have ever achieved.